Pharming Launches Joenja in Japan for APDS Patients
LEIDEN, Netherlands, August 13, 2026 Pharming Group N.V. announced the commercial launch of Joenja® (leniolisib) in Japan for adults...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology immunology Immunotherapy Medical Devices Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
LEIDEN, Netherlands, August 13, 2026 Pharming Group N.V. announced the commercial launch of Joenja® (leniolisib) in Japan for adults...
MILAN, Italy, August 11, 2026 Bracco Imaging has announced that its VueJect® ultrasound contrast delivery system has received 510(k)...
BOLOGNA AND MILAN, Italy, August 13, 2026 Alfasigma S.p.A. has entered into a share purchase agreement with SEVER Life...
AUSTIN, Texas, August 5, 2026 Natera, Inc. has submitted an application to Japan’s Pharmaceuticals and Medical Devices Agency (PMDA)...
Zug, Switzerland | July 20, 2026 Galderma announced the expansion of its Alastin® regenerative skincare brand across the Japan...
MELBOURNE, Australia, and TOKYO, Japan, July 17, 2026 Telix Pharmaceuticals has completed patient enrollment in its pivotal Phase 3...
PARIS | June 19, 2026 Sanofi announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved the...
MILAN, Italy & HYOGO, Japan | December 24, 2025 — Italfarmaco and JCR Pharmaceuticals have announced a landmark commercialisation...
